. 2018 Jul 8;11:1756284818785571. doi: 10.1177/1756284818785571

Table 1.

Summary of data from included studies.

First author^ref	Country	Retro/prospective	Time from surgery (months)	RS for recurrence	FC assay	Total pts	FC 50 µg/g				FC 100 µg/g				FC 150 µg/g				FC 200 µg/g
First author^ref	Country	Retro/prospective	Time from surgery (months)	RS for recurrence	FC assay	Total pts	TP	FP	TN	FN	TP	FP	TN	FN	TP	FP	TN	FN	TP	FP	TN	FN
Orlando²⁸	Italy	Prosp	3	2	ELISA	39	18	15	5	1	15	11	9	4	15	9	11	4	12	5	15	7
Lobaton¹⁶	Spain	Prosp	NS	2	ELISA	30	–	–	–	–	10	8	10	2	10	6	12	2	9	6	12	3
Yamamoto⁴⁶	Japan	Prosp	7.2 ± 0.4	2	ELISA	20	10	8	2	0	10	6	4	0	6	2	8	4	5	0	10	5
Lasson²⁴	Sweden	Prosp	12	2	ELISA	30	–	–	–	–	11	11	6	2	–	–	–	–	7	8	9	6
Boschetti⁴⁸	France	Prosp	8.2 ± 0.5	2	ELISA	86	42	29	14	1	41	18	25	2	33	8	35	10	–	–	–	–
Wright³¹	Australia	Prosp	18	2	ELISA	68	21	29	16	2	20	18	27	3	17	14	31	6	15	14	31	8
Bachiller⁴⁷	Spain	Retro	NS	2b	ELISA	97	35	33	24	5	30	27	30	10	20	21	36	20	14	16	41	26
Garcia-Planella²⁶	Spain	Prosp	63.9 ± 72.5	2	ELISA	88 (119 ICs done)	42	51	19	7	34	25	45	15	–	–	–	–	–	–	–	–
Lopes⁵⁰	Portugal	Prosp	87.5	2	ELISA	99	54	7	17	21	36	5	19	39	–	–	–	–	–	–	–	–

FC, fecal calprotectin; FN, false negatives; FP, false positives; IC, ileocolonoscopy; NS, not specified; pts, patients; Prosp, prospective; RS, Rutgeerts score; TN, true negatives; TP, true positives.